Search

Displaying results 6311 - 6320 of 10000 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.

  3. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]

  4. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    It is no longer used in the United States.

  5. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive … The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.

  6. Drug

    Medical air

    go.drugbank.com/drugs/DB09337
    ApprovedInvestigationalVet approved

    Medical air is supplied by a special air compressor to patient care areas using clean outside air.

  7. Drug

    Mubodina

    go.drugbank.com/drugs/DB17616
    Experimental

    It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome. … Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.

    Synonyms: Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1
  8. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  9. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  10. Drug

    AN0128

    go.drugbank.com/drugs/DB05054
    Investigational

    Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.